We are live on
!
Find out more
TA
Tamarack Advisers Portfolio holdings
AUM
$2.12M
1-Year Est. Return
58.09%
This Fund
S&P 500
This Quarter
Est. Return
-21.08%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$245M
AUM Growth
-$105M
(-30%)
Cap. Flow
-$36.6M
Cap. Flow
% of AUM
-14.91%
Top 10 Holdings %
Top 10 Hldgs %
79.64%
Holding
33
New
3
Increased
11
Reduced
4
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
MDRX
Veradigm Inc. Common Stock
MDRX
|
+$12.3M |
| 2 |
AtriCure
ATRC
|
+$10.1M |
| 3 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$8.23M |
| 4 |
McKesson
MCK
|
+$6.24M |
| 5 |
Rigel Pharmaceuticals
RIGL
|
+$2.68M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Labcorp
LH
|
+$27.8M |
| 2 |
CORI
Corium International, Inc.
CORI
|
+$13.6M |
| 3 |
Gilead Sciences
GILD
|
+$13.5M |
| 4 |
Pacira BioSciences
PCRX
|
+$7.37M |
| 5 |
HOLX
Hologic
HOLX
|
+$6.15M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 84.71% |
| 2 | Industrials | 6.36% |
| 3 | Consumer Discretionary | 4.51% |
| 4 | Communication Services | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MDRX
1
DELISTED
Veradigm Inc. Common Stock
MDRX
| $29.4M | 11.99% |
3,050,000
+1,100,000
| +56% | +$12.3M |
|
2
Medtronic
MDT
$109B
| $25M | 10.2% |
275,000
+15,000
| +6% | +$1.4M |
|
|
NUVA
3
DELISTED
NuVasive, Inc.
NUVA
| $24.8M | 10.1% |
500,000
-25,000
| -5% | -$1.5M |
|
4
NovoCure
NVCR
$1.73B
| $22.4M | 9.15% |
670,000
+35,000
| +6% | +$1.28M |
|
|
5
AtriCure
ATRC
$1.92B
| $18.4M | 7.49% |
600,000
+325,000
| +118% | +$10.1M |
|
|
NXTM
6
DELISTED
NxStage Medical Inc.
NXTM
| $17.9M | 7.29% |
625,000
+25,000
| +4% | +$710K |
|
|
SRCL
7
DELISTED
Stericycle Inc
SRCL
| $15.6M | 6.36% |
425,000
+55,000
| +15% | +$2.58M |
|
8
Lantheus
LNTH
$6.49B
| $15.3M | 6.22% |
975,000
+5,000
| +0.5% | +$76.6K |
|
9
Bio-Rad Laboratories Class A
BIO
$8.71B
| $13.9M | 5.68% |
60,000
-5,000
| -8% | -$1.34M |
|
|
10
Rigel Pharmaceuticals
RIGL
$681M
| $12.7M | 5.16% |
550,000
+95,000
| +21% | +$2.68M |
|
11
Service Corp International
SCI
$11.7B
| $11.1M | 4.51% |
275,000
+61,144
| +29% | +$2.66M |
|
|
HOLX
12
DELISTED
Hologic
HOLX
| $8.22M | 3.35% |
200,000
-150,000
| -43% | -$6.15M |
|
|
PTLA
13
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $7.81M | 3.18% |
+400,000
| New | +$8.23M |
|
|
14
McKesson
MCK
$100B
| $5.52M | 2.25% |
+50,000
| New | +$6.24M |
|
|
CORV
15
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
| $5.29M | 2.16% |
2,125,000
+65,000
| +3% | +$216K |
|
|
HIND
16
Vyome Holdings
HIND
$14.9M
| – | – |
0
| – | – |
|
|
VSI
17
DELISTED
Vitamin Shoppe Inc.
VSI
| $2.84M | 1.16% |
600,000
| – | – |
|
|
OPTN
18
DELISTED
OptiNose
OPTN
| $1.86M | 0.76% |
20,000
-37,333
| -65% | -$5.33M |
|
|
STRM
19
DELISTED
Streamline Health Solutions
STRM
| $1.58M | 0.64% |
130,000
+3,333
| +3% | +$45.1K |
|
|
ISEE
20
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $1.2M | 0.49% |
1,000,000
| – | – |
|
|
PTLA
21
CALL
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $175K | 0.07% |
+3,500
| New | +$72K |
|
22
CALL
Alkermes
ALKS
$8.22B
| – | – |
-2,000
| Closed | -$696K |
|
23
PUT
Amgen
AMGN
$208B
| – | – |
-200
| Closed | -$197K |
|
|
24
CALL
Gilead Sciences
GILD
$162B
| – | – |
-2,500
| Closed | -$340K |
|
|
25
Gilead Sciences
GILD
$162B
| – | – |
-175,000
| Closed | -$13.5M |
|
Similar funds
SCM
LBC
ICM
LCMP
GIP
STC
GC
DU
Tamarack Advisers's Q4 2018 Portfolio in Review
As of Q4 2018, Tamarack Advisers held 33 positions worth $245M, down 30% from $350M the previous quarter. Its ten largest holdings account for 80% of the portfolio.
Tamarack Advisers withdrew a net $36.6M in Q4 2018, closing 12 positions and reducing 4 holdings. Its most notable exit was Labcorp, an estimated $27.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 88% a quarter earlier, followed by Industrials and Consumer Discretionary.
Against the trend, Tamarack Advisers opened a new position in Portola Pharmaceuticals, Inc. worth $7.81M.
- Tamarack Advisers's largest Q4 2018 buy was Portola Pharmaceuticals, Inc.: 400,000 shares worth $7.81M.
- Tamarack Advisers added most to Veradigm Inc. Common Stock in Q4 2018, an estimated $12.3M increase.
- Tamarack Advisers's biggest Q4 2018 reduction was Hologic, cutting an estimated $6.15M.
- Tamarack Advisers fully exited Labcorp in Q4 2018, selling an estimated $27.8M.
- Tamarack Advisers's ten largest holdings make up 80% of its $245M portfolio in Q4 2018.
- Tamarack Advisers opened 3 new positions and closed 12 in Q4 2018.
- Tamarack Advisers's portfolio value fell 30% quarter-over-quarter to $245M.
Based on Tamarack Advisers's 13F filing for Q4 2018, filed 11 Feb 2019.